Literature DB >> 23997993

Contribution of Myofibroblasts of Different Origins to Liver Fibrosis.

Michel Fausther1, Elise G Lavoie, Jonathan A Dranoff.   

Abstract

The most common cause of liver failure is cirrhosis, due to progressive liver fibrosis and other architectural changes in the liver. Fibrosis occurs after liver injury or stress and results directly from an imbalance between the processes of extracellular matrix synthesis (fibrogenesis) and degradation (fibrolysis). Although research studies have identified several promising targets at the molecular level, current therapies to prevent and treat hepatic fibrosis in patients have only shown limited success. It is well established that liver myofibroblasts are the primary effector cells responsible for the extensive extracellular matrix accumulation and scar formation observed during hepatic fibrosis, in both clinical and experimental settings. Thus, as the major fibrogenic cells implicated in wound healing and tissue repair response, liver myofibroblasts could represent excellent targets for antifibrotic therapies. Still, the exact natures and identities of liver myofibroblasts precursors have yet to be resolved, and their relative contribution to hepatic fibrosis to be determined. The goal of this review is to examine the relative importance of liver myofibroblast precursors in the pathogenesis of liver fibrosis.

Entities:  

Keywords:  Bone marrow-derived fibrocytes; Bone marrow-derived mesenchymal stem cells; Hepatic stellate cells; Mesothelial cells; Myofibroblasts; Pathobiology; Portal fibroblasts

Year:  2013        PMID: 23997993      PMCID: PMC3755779          DOI: 10.1007/s40139-013-0020-0

Source DB:  PubMed          Journal:  Curr Pathobiol Rep        ISSN: 2167-485X


  72 in total

1.  Comparative proteomic analysis of rat hepatic stellate cell activation: a comprehensive view and suppressed immune response.

Authors:  Juling Ji; Feng Yu; Qiuhong Ji; Zhiyao Li; Kuidong Wang; Jinsheng Zhang; Jinbiao Lu; Li Chen; Qun E; Yaoying Zeng; Yuhua Ji
Journal:  Hepatology       Date:  2012-06-06       Impact factor: 17.425

Review 2.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 3.  Liver fibrogenic cells.

Authors:  Stuart J Forbes; Maurizio Parola
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

4.  Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR.

Authors:  Melissa A Passino; Ryan A Adams; Shoana L Sikorski; Katerina Akassoglou
Journal:  Science       Date:  2007-03-30       Impact factor: 47.728

5.  The bone marrow functionally contributes to liver fibrosis.

Authors:  Francesco P Russo; Malcolm R Alison; Brian W Bigger; Eunice Amofah; Aikaterini Florou; Farhana Amin; George Bou-Gharios; Rosemary Jeffery; John P Iredale; Stuart J Forbes
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

Review 6.  The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

7.  Hepatic stellate cells support hematopoiesis and are liver-resident mesenchymal stem cells.

Authors:  Claus Kordes; Iris Sawitza; Silke Götze; Dieter Häussinger
Journal:  Cell Physiol Biochem       Date:  2013-02-28

Review 8.  Vitamin A-storing cells (stellate cells).

Authors:  Haruki Senoo; Naosuke Kojima; Mitsuru Sato
Journal:  Vitam Horm       Date:  2007       Impact factor: 3.421

9.  Immunocytochemical detection of desmin in fat-storing cells (Ito cells).

Authors:  Y Yokoi; T Namihisa; H Kuroda; I Komatsu; A Miyazaki; S Watanabe; K Usui
Journal:  Hepatology       Date:  1984 Jul-Aug       Impact factor: 17.425

10.  Characterization of endothelin receptors mediating rat hepatic stellate cell contraction.

Authors:  D C Rockey
Journal:  Biochem Biophys Res Commun       Date:  1995-02-15       Impact factor: 3.575

View more
  25 in total

1.  An Elf2-like transcription factor acts as repressor of the mouse ecto-5'-nucleotidase gene expression in hepatic myofibroblasts.

Authors:  Michel Fausther; Elise G Lavoie; Jessica R Goree; Jonathan A Dranoff
Journal:  Purinergic Signal       Date:  2017-06-30       Impact factor: 3.765

2.  Anti-TGFβ-1 receptor inhibitor mediates the efficacy of the human umbilical cord mesenchymal stem cells against liver fibrosis through TGFβ-1/Smad pathway.

Authors:  Ji Xuan; Wang Feng; Zheng-Tao An; Jian Yang; Hua-Bing Xu; Jing Li; Zhi-Fei Zhao; Wei Wen
Journal:  Mol Cell Biochem       Date:  2017-02-08       Impact factor: 3.396

3.  Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent.

Authors:  Diptadip Dattaroy; Ratanesh Kumar Seth; Sutapa Sarkar; Diana Kimono; Muayad Albadrani; Varun Chandrashekaran; Firas Al Hasson; Udai P Singh; Daping Fan; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Eur J Pharmacol       Date:  2018-09-05       Impact factor: 4.432

4.  Fibroblast-Extracellular Matrix Interactions in Tissue Fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Curr Pathobiol Rep       Date:  2016-02-05

5.  Portal Fibroblasts in Biliary Fibrosis.

Authors:  Rebecca G Wells
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

Review 6.  The portal fibroblast: not just a poor man's stellate cell.

Authors:  Rebecca G Wells
Journal:  Gastroenterology       Date:  2014-05-09       Impact factor: 22.682

7.  Epithelial-mesenchymal transition in liver fibrosis.

Authors:  Ya-Lei Zhao; Rong-Tao Zhu; Yu-Ling Sun
Journal:  Biomed Rep       Date:  2016-01-25

8.  Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis.

Authors:  Luigi Locatelli; Massimiliano Cadamuro; Carlo Spirlì; Romina Fiorotto; Silvia Lecchi; Carola Maria Morell; Yury Popov; Roberto Scirpo; Maria De Matteis; Mariangela Amenduni; Andrea Pietrobattista; Giuliano Torre; Detlef Schuppan; Luca Fabris; Mario Strazzabosco
Journal:  Hepatology       Date:  2016-01-16       Impact factor: 17.425

9.  The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis.

Authors:  Mahmoud Elshal; Nashwa Abu-Elsaad; Amr El-Karef; Tarek Mostafa Ibrahim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-14       Impact factor: 3.000

Review 10.  Neovascularization is a key feature of liver fibrosis progression: anti-angiogenesis as an innovative way of liver fibrosis treatment.

Authors:  Mariia Zadorozhna; Sante Di Gioia; Massimo Conese; Domenica Mangieri
Journal:  Mol Biol Rep       Date:  2020-02-10       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.